# Clonazepam: Pharmacology, Clinical Applications, and Interprofessional Management

**F. Y. Wu[1], Christ King[2]**

1. Virginia Mason Medical Center, Department of General, Thoracic and Vascular Surgery

2. Department of Anesthesia, PeaceHealth

**Abstract:** Clonazepam, a potent benzodiazepine, holds a significant position in the treatment landscape for various neurological and psychiatric conditions. Approved by the FDA for seizure disorders and panic disorder, its spectrum of use extends to REM sleep behavior disorder and acute mania. Despite its therapeutic efficacy, concerns regarding misuse, adverse effects, and long-term dependence necessitate a comprehensive understanding of its pharmacology and clinical implications. This review provides an in-depth exploration of clonazepam's mechanisms of action, indications, dosing, adverse effects, and considerations for interprofessional management. By synthesizing current evidence and clinical insights, it aims to equip healthcare professionals with the knowledge required to navigate clonazepam therapy effectively and promote safe prescribing practices.

**Keywords:** Clonazepam, benzodiazepine, pharmacology, clinical applications, adverse effects, interprofessional management, seizure disorders, panic disorder, REM sleep behavior disorder, acute mania.

**Key Points:**

**Pharmacological Profile:** Clonazepam, a long-acting benzodiazepine, acts as a positive allosteric modulator of GABA-A receptors, exerting anxiolytic, anticonvulsant, and sedative effects.

**Clinical Indications:** FDA-approved for seizure disorders and panic disorder, clonazepam also demonstrates efficacy in managing REM sleep behavior disorder and acute mania, albeit with careful consideration of its adverse effect profile.

**Dosing and Administration:** Initiation and titration of clonazepam should follow individual patient response, with consideration for factors such as age, comorbidities, and concurrent medications. Dosing regimens may vary based on the indication, patient age, and renal or hepatic function.

**Adverse Effects:** Common adverse effects of clonazepam include sedation, drowsiness, and motor impairment, while less common effects encompass confusion, irritability, and paradoxical disinhibition. Long-term use may lead to tolerance, dependence, and withdrawal symptoms upon discontinuation.

**Special Populations:** Caution is warranted in specific patient populations, including the elderly, pregnant or breastfeeding individuals, and those with hepatic or renal impairment, due to variations in drug metabolism and potential for adverse effects.

**Interprofessional Management:** Collaborative efforts among clinicians, nurses, pharmacists, and primary care providers are essential to ensure appropriate prescribing, monitoring, and patient education. Utilization of resources such as controlled substance monitoring programs can aid in promoting safe medication practices and preventing misuse.

**Future Directions:** Ongoing research is necessary to further elucidate clonazepam's efficacy and safety profile, particularly in emerging indications and special populations. Interdisciplinary collaboration and evidence-based practices will continue to shape the optimal use of clonazepam in clinical practice.

**Introduction:**

Clonazepam, a long-acting benzodiazepine, stands as a cornerstone in the pharmacological armamentarium for various neurological and psychiatric conditions. Approved by the FDA for the treatment of seizure disorders and panic disorder, its versatility extends to managing conditions like REM sleep behavior disorder and acute mania. However, its potent pharmacological profile warrants careful consideration, particularly regarding its potential for misuse, adverse effects, and long-term dependence.

In this comprehensive review, we delve into the pharmacology, clinical applications, adverse effects, and considerations for interprofessional management of clonazepam. We explore its mechanisms of action, indications, dosing regimens, and monitoring strategies, while also addressing critical aspects such as patient populations at risk, drug interactions, and outcomes associated with its use.

By synthesizing current evidence and clinical insights, this review aims to provide healthcare professionals with a nuanced understanding of clonazepam's role in therapeutic practice. Additionally, it underscores the importance of interdisciplinary collaboration in optimizing patient care and ensuring the safe and judicious use of this medication.

**Uses:**

Clonazepam, a long-acting benzodiazepine with high potency, exerts its pharmacological effects as a GABA-A receptor agonist and also demonstrates serotonergic activity by increasing serotonin synthesis.[1] FDA-approved for the treatment of seizure and panic disorders, clonazepam possesses both anticonvulsant and anxiolytic properties.[2][3] Additionally, it is utilized off-label as monotherapy or adjunctive therapy for various conditions, including mania, restless leg syndrome, insomnia, tardive dyskinesia, and REM sleep behavior disorder.[4][5][6]

**Seizure Disorders**: Clonazepam exhibits efficacy across a spectrum of seizure disorders, serving as an acute management option for epilepsy and non-convulsive status epilepticus. It effectively controls minor motor seizures such as petit mal absences, Lennox-Gastaut syndrome, and infantile spasms.[7] While not typically a first-line therapy for other seizure types, it may be considered for patients resistant to standard treatment.

**Panic Disorder**: Clonazepam demonstrates significant improvement in patients with panic disorder, with or without agoraphobia. Its longer half-life mitigates the risk of rebound anxiety upon discontinuation, making it suitable for short-term management and acute treatment of panic attacks.[8]

**Acute Mania**: With its anticonvulsant and serotonin agonist activities, clonazepam offers efficacy in the treatment of acute mania. Research suggests its superiority over lithium in reducing manic symptoms, leading to decreased reliance on antipsychotic medications and mitigating associated side effects.[3] A combination of clonazepam and the antipsychotic haloperidol is considered highly effective for acute agitation in emergency settings.[9]

**Miscellaneous Uses**: Clonazepam is increasingly recognized for its utility in treating akathisia, restless leg syndrome, and bruxism.[10][11][12] The American Academy of Sleep Medicine (AASM) recommends clonazepam for REM sleep behavior disorder (RBD), while topical formulations are being investigated for burning mouth syndrome.[13][14][15]

In summary, clonazepam's versatility extends beyond its approved indications, offering therapeutic options for a range of neurological and psychiatric conditions. Ongoing research underscores its evolving role in clinical practice, particularly in the management of sleep-related disorders and oromandibular dyskinesias.

**Mode of Action:**

Clonazepam, a highly potent and long-acting benzodiazepine, operates by positively modulating GABA-A receptors, crucial components of the central nervous system. GABA-A receptors, classified as ligand-gated chloride ion channels, are activated by the endogenous neurotransmitter GABA (gamma-aminobutyric acid). Clonazepam enhances GABA-A receptor function by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased firing activity. This mechanism ultimately produces calming effects on the brain, reducing neuronal excitability.[16]

GABA serves as an inhibitory neurotransmitter abundant in cortical and limbic regions. While there are three types of GABA receptors (A, B, and C), benzodiazepines like clonazepam selectively target GABA-A receptors. These receptor complexes consist of five subunits—two alpha, two beta, and one gamma—each with two GABA-binding sites and one benzodiazepine-binding site. Unlike GABA, benzodiazepines bind to specific sites at the interface between the alpha and gamma subunits of the receptor complex, inducing a conformational change in the chloride channel. This alteration leads to hyperpolarization of the cell, reinforcing GABA's inhibitory effect across the central nervous system.[17]

GABA-A receptors further divide into various subtypes based on alpha subunit isoforms, influencing the distribution and function of benzodiazepine binding. Benzodiazepine type-1 receptors (BZ1), containing alpha-1 subunits, predominate in the cortex, thalamus, and cerebellum, contributing to anticonvulsant and sedative effects. In contrast, benzodiazepine type-2 receptors (BZ2), with alpha-2 subunits, are concentrated in the limbic system, motor neurons, and spinal cord dorsal horn, mediating anxiolytic effects.[17]

Clonazepam's modulation of GABA-A receptors, particularly through BZ1 and BZ2 receptor subtypes, underlies its therapeutic actions in managing seizure disorders, panic disorder, and other neurological conditions. Understanding these intricate mechanisms illuminates the drug's pharmacological profile and aids in optimizing its clinical use.

**Pharmacokinetics:**

**Absorption:** Clonazepam exhibits rapid absorption following oral administration, with peak plasma concentrations typically achieved within one to four hours post-dose.

**Distribution:** Approximately 85% of clonazepam is bound to plasma proteins. Notably, its lower lipid solubility distinguishes it from other high-potency benzodiazepines, resulting in a reduced likelihood of causing anterograde amnesia.

**Metabolism:** Clonazepam undergoes extensive hepatic metabolism primarily via the cytochrome P-450 enzyme system, notably CYP3A, in a dose-dependent manner.

**Excretion:** The elimination half-life of clonazepam ranges from 30 to 40 hours. Its primary metabolite, 7-amino-clonazepam, is predominantly excreted in the urine.[18]

Understanding clonazepam's pharmacokinetic profile provides insights into its onset of action, duration of effect, and potential for drug interactions, guiding dosing strategies and clinical management.

**Administration**

**Dosage Forms:** Clonazepam is available in immediate-release tablet formulations of 0.5 mg, 1 mg, and 2 mg strengths, as well as orally disintegrating tablets (ODT) ranging from 0.125 mg to 2 mg.

**Dosage and Administration: General Considerations:** Clonazepam is typically administered once daily at bedtime to mitigate daytime somnolence. For orally disintegrating tablets (ODT), patients should swallow the tablet with water immediately after removing it from the package.

**Treatment of Absence Seizures, Petit Mal Variant (Lennox-Gastaut syndrome), and Akinetic and Myoclonic Seizures (myoclonia): Adults and Adolescents (Weight > 30 kg):** Initiate therapy with 0.5 mg tablets orally three times daily. Adjust dosage by increments of 0.5 to 1 mg every three days until seizure control is achieved, not exceeding a maximum daily dose of 20 mg.

**Geriatric Patients:** Administer the same dosage as adults, but exercise caution with lower initial doses due to potential increased sensitivity to benzodiazepine effects.

**Pediatric Patients (Weight < 30 kg):** Initially, administer orally at a dosage of 0.01 to 0.03 mg/kg/day (not to exceed 0.05 mg/kg/day) divided into two or three doses. The maximum daily dose should not exceed 0.1 to 0.2 mg/kg in three doses.

**Treatment of Panic Disorder:** Initiate treatment with 0.25 mg tablets orally twice daily for three days, followed by dose escalation to 0.5 mg tablets twice daily. The maximum daily dose should not exceed 1 to 4 mg.

**Treatment of REM Sleep Behavior Disorder (RBD):** As recommended by the American Academy of Sleep Medicine (AASM), administer clonazepam at a dosage ranging from 0.25 mg to 2 mg orally 30 minutes before bedtime.[13]

Adherence to prescribed dosage regimens and careful titration are essential to optimize therapeutic outcomes while minimizing adverse effects. Close monitoring, particularly in vulnerable populations such as pediatric and geriatric patients, is crucial to ensure safety and efficacy.

**Use in Specific Patient Populations**

**Pregnancy Considerations:** Clonazepam, previously classified as an FDA pregnancy class D drug, has been associated with certain fetal malformations, though data remain inconclusive. Late pregnancy use may result in floppy infant syndrome or severe neonatal withdrawal symptoms. Clinical use during pregnancy should be carefully weighed against potential fetal risks, with benefits outweighing risks.[19][20]

**Breastfeeding Considerations:** While clonazepam is excreted into breast milk, the amount is typically not significant. However, premature neonates or those exposed during pregnancy may be at risk due to impaired metabolic pathways. Breastfeeding mothers should be cautioned, and neonates monitored for potential adverse effects, ideally avoiding clonazepam use while breastfeeding.[19]

**Liver Impairment and/or Renal Impairment:** Manufacturer labeling lacks dosage adjustment recommendations for hepatic or renal impairment. Caution is advised in such patients due to clonazepam's hepatic metabolism and renal excretion, potentially leading to drug accumulation and toxicity. Severe liver disease warrants contraindication of clonazepam use.[21][22]

**Geriatric Population:** Benzodiazepines, including clonazepam, are considered Potentially Inappropriate Medications (PIM) by the American Geriatric Society (AGS Beers Criteria). They may induce cognitive impairment, delirium, falls, and fractures in older adults. Nonetheless, their use may be warranted for seizure disorders and severe generalized anxiety disorder, with caution exercised to minimize adverse effects.[23]

Understanding the nuances of clonazepam's use in specific patient populations is crucial for optimizing therapeutic outcomes while mitigating potential risks, ensuring safe and effective pharmacotherapy. Close monitoring and individualized treatment plans are paramount in vulnerable patient groups.

**Adverse Effects**

Clonazepam, as a central nervous system depressant, shares common adverse effects with other benzodiazepine drugs, primarily manifesting as sedation and motor impairment.

**Common Side Effects:**

- Lethargy
- Fatigue
- Sedation
- Drowsiness
- Motor impairment (impaired coordination, impaired balance, dizziness)[17][24]

**Less Common Side Effects:**

- Blurred vision
- Confusion
- Irritability
- Loss of libido
- Lack of motivation
- Psychomotor agitation
- Hallucinations
- Worsening of depression

- Short-term memory loss
- Anterograde amnesia, particularly with high doses[25][26][27]

**Occasional Side Effects:**

- Personality changes
- Behavioral disturbances
- Ataxia
- Increased frequency of seizures
- Thrombocytopenia
- Dysphoria[28][29][30]

**Rare Side Effects:**

- Paradoxical disinhibition (e.g., excitement, rage, impulsive behavior), particularly in older patients
- Suicide
- Psychosis
- Incontinence
- Long-term use associated with depression and sexual dysfunction
- Lichenoid drug eruption
- Paradoxical sleep-related eating disorder (SRED), despite clonazepam's use in treating SRED[31][32][33][34][35][36][37]

**Drug-Drug Interactions:**

- Concurrent use of benzodiazepines and opioids may result in severe CNS depression, respiratory depression, coma, or death. Combination should be avoided[38].
- Concurrent use of clonazepam with kratom may lead to increased CNS depression and death. Avoid combination[39].
- Concurrent administration with antidepressants, antipsychotics, hypnotics, antiepileptic drugs, and antihistamines can increase sedation due to pharmacodynamic synergism. Therapy should be monitored[40].
- Concurrent administration with CYP3A4 inducers or inhibitors can respectively decrease or increase clonazepam serum concentrations, warranting caution and potential dosage adjustments[41][42].

Awareness of potential adverse effects and drug interactions with clonazepam is essential for clinicians to make informed decisions regarding treatment initiation, dosage adjustments, and patient monitoring, thereby optimizing therapeutic outcomes while minimizing risks.

**Contraindications**

1. **Narrow-angle Glaucoma:** Clonazepam, as a benzodiazepine (BZD) drug, is generally contraindicated in acute closed-angle glaucoma. The potential relaxation of the iris and mild anticholinergic activity associated with BZDs can precipitate an acute glaucoma attack.[43]
2. **Significant Liver Disease:** Due to clonazepam's extensive hepatic metabolism, significant liver disease can impair benzodiazepine oxidation, leading to drug accumulation, excessive sedation, and respiratory depression.[21]
3. **Hypersensitivity to Drug or Components:** While rare, hypersensitivity reactions to clonazepam or its formulation components may occur.

**Boxed Warning:**

- **Concurrent Use with Opioids:** Combination therapy with benzodiazepines and opioids may result in severe sedation, respiratory depression, coma, and even death. Avoid concurrent use.
- **Risk of Misuse and Addiction:** Benzodiazepines, including clonazepam, carry a risk of misuse and addiction. Commonly associated with concurrent alcohol or illicit substance use, including opioids.
- **Risk of Dependence and Withdrawal:** Prolonged use of clonazepam can lead to physical dependence. Abrupt discontinuation or rapid dosage reduction after sustained use may precipitate life-threatening acute withdrawal symptoms. A risk mitigation strategy involves gradual dose reduction.[38]

Awareness of these contraindications and boxed warnings is essential for healthcare providers to ensure safe prescribing practices and minimize potential risks associated with clonazepam therapy.

**Monitoring During Clonazepam Therapy**

1. **Complete Blood Count, Renal, and Liver Function:**
    - Regular monitoring of hepatic and renal function, along with a complete blood count, is essential due to clonazepam's hepatic metabolism and renal excretion. Thrombocytopenia should also be monitored due to rare occurrences.[22]

2. **Worsening of Seizures:**
    - Patients with multiple seizure disorders may experience worsening seizures with clonazepam. Dosing adjustments or dose increases may be necessary in such cases.
3. **Abrupt Discontinuation and Tolerance:**
    - Avoid abrupt withdrawal, especially in patients on long-term, high-dose therapy, as it may precipitate status epilepticus and withdrawal symptoms. Long-term use can lead to tolerance development, particularly to its anticonvulsant properties.
4. **Respiratory Compromise:**
    - Extreme caution is advised in patients with compromised respiratory function, such as asthma, COPD, or obstructive sleep apnea, due to the increased risk of respiratory depression. Clonazepam's propensity to cause hypersalivation may exacerbate conditions with difficulty managing secretions.
5. **Impaired Cognitive and Motor Performance:**
    - Patients should be cautioned about potential CNS depression, which may impair judgment, thinking, and motor skills. Activities requiring higher motor skills, such as driving or operating heavy machinery, should be avoided. Geriatric patients and those with neuromuscular disorders require particular attention due to increased fall risk.
6. **Suicidal Behavior:**
    - Clonazepam is associated with an elevated risk of depression, suicidal behavior, and thoughts. Patients and caregivers should monitor for worsening depression, mood changes, or suicidal ideation.
7. **Alcohol Use:**
    - Concomitant use of clonazepam and alcohol should be strongly discouraged due to their combined CNS depressant effects, which can lead to severe respiratory depression, hypotension, and death.
8. **Monitoring for Misuse/Abuse:**
    - Clonazepam is classified as a DEA-schedule IV drug. Utilizing a prescription drug monitoring program (PDMP) can help identify potential misuse or abuse.[44]

Regular monitoring and careful assessment of patients receiving clonazepam therapy are essential to ensure treatment efficacy, minimize adverse effects, and prevent potential complications.

**Toxicity of Clonazepam**

**Therapeutic Range and Toxic Levels:**

- The therapeutic range of clonazepam is typically between 0.02 to 0.08 mcg/mL. Levels exceeding 0.08 mcg/mL are considered toxic.

**Initial Presentation:**

- Symptoms of clonazepam overdose manifest rapidly, with initial CNS depression symptoms including:
    - Somnolence
    - Diplopia
    - Slurred speech
    - Motor impairment

**Severe Presentation:**

- Severe overdose may lead to critical symptoms such as:
    - Respiratory depression
    - Hypoxemia
    - Apnea
    - Hypotension
    - Bradycardia
    - Cardiac arrest
    - Pulmonary aspiration
    - Coma

**Increased Toxicity with Concurrent CNS Depressants:**

- Toxicity risk significantly escalates when clonazepam is combined with other CNS depressants like opioids, ethanol, or barbiturates.[45]

**Treatment of Toxicity:**

- Supportive care is paramount, involving:
    - Monitoring vital signs
    - Administering IV fluids for hypotension

- Atropine for bradycardia
- Maintaining airway patency via intubation or artificial respiration if respiratory depression arises.

**Use of Flumazenil as Antidote:**

- Flumazenil, a competitive benzodiazepine receptor antagonist, is controversial as an antidote. Its use may lower seizure threshold and widen QRS complex, leading to adverse effects. Therefore, its benefits do not outweigh the risks, and consultation with a medical toxicologist is advisable before administration. Flumazenil is not recommended for multidrug toxicity.[46]

**Addressing Illicit Benzodiazepine Use:**

- Illicit benzodiazepine use in conjunction with opioids is on the rise, resulting in heightened toxicity and mortality rates. Increased awareness among healthcare providers, patient education, and community involvement are crucial in addressing the hazards associated with illicit benzodiazepine use.

**Outcomes Concerning Clonazepam Use**

Inappropriate long-term use of clonazepam and other benzodiazepine (BZD) drugs despite their serious adverse effects prompts concern within the healthcare community. Risks include falls, cognitive impairment, and addiction. Addressing this issue requires coordinated efforts from an interprofessional team comprising clinicians, nurses, pharmacists, and primary care providers.

**Initiation and Continuation:**

- Clonazepam is often initiated during or after acute events in hospital settings by clinicians, with nurses typically administering the drug. However, its continuation post-hospitalization, without appropriate indication, poses challenges. Pharmacists play a crucial role in medication reconciliation during discharge, ensuring appropriate prescribing.

**Patient Influence and Misconceptions:**

- Patients may perceive clonazepam and BZDs as "wonder drugs" for improving sleep and overall well-being, influencing clinicians' decisions. This misconception can lead to poor outcomes such as drug dependence, misuse, and motor impairment.

**Interprofessional Approach:**

- An interprofessional approach is essential to develop strategies for reducing hypnotic use and preventing misuse across hospital, primary, and secondary care settings.

**Utilization of CSPMP Databases:**

- Clinicians, nurses, and pharmacists should utilize Controlled Substance Prescription Monitoring Program (CSPMP) databases to ensure safe and appropriate use of benzodiazepines, sedative-hypnotics, opioids, and other controlled substances.

**Enhancing Safe Medication Practices:**

- Research suggests that interprofessional teamwork involving primary care physicians, mid-level practitioners, nurses, and pharmacists can enhance safe medication practices, particularly concerning high-risk benzodiazepines.

By leveraging the expertise of each team member and utilizing tools like CSPMP databases, healthcare professionals can mitigate the risks associated with inappropriate clonazepam use, ultimately improving patient outcomes and promoting safe medication practices.

**Conclusion:**

In conclusion, clonazepam, a potent benzodiazepine, serves as a valuable therapeutic agent in managing various conditions such as seizure disorders, panic disorder, and REM sleep behavior disorder. However, its efficacy must be balanced against the potential for adverse effects and misuse. The medication's initiation, continuation, and monitoring require careful consideration by an interprofessional healthcare team to ensure safe and appropriate use.

Concerns regarding the inappropriate long-term use of clonazepam underscore the importance of collaborative efforts among clinicians, nurses, pharmacists, and primary care providers. Utilization of tools like Controlled Substance Prescription Monitoring Program (CSPMP) databases can aid in promoting safe medication practices and preventing misuse.

Moving forward, it is imperative to educate both healthcare professionals and patients about the risks associated with clonazepam use and to develop interventions aimed at reducing inappropriate prescribing and promoting responsible medication management. By adopting an interprofessional approach and leveraging available resources, we can optimize the benefits of clonazepam therapy while minimizing potential harm, ultimately improving patient outcomes and enhancing overall healthcare quality.

**Declaration:**

No conflict of interest.

**References**


1. Chouinard G, Labonte A, Fontaine R, Annable L. New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(4-6):669-73. [PubMed]
2. Cloos JM. The treatment of panic disorder. Curr Opin Psychiatry. 2005 Jan;18(1):45-50. [PubMed]

3. Chouinard G. The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci. 2006 May;31(3):168-76. [PMC free article] [PubMed]
4. Curtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord. 2004 Mar;78(3):201-8. [PubMed]
5. [Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts]. Arq Neuropsiquiatr. 2007 Sep;65(3A):721-7. [PubMed]
6. Khouzam HR. Identification and management of tardive dyskinesia: A case series and literature review. Postgrad Med. 2015;127(7):726-37. [PubMed]
7. Pinder RM, Brogden RN, Speight TM, Avery GS. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 1976 Nov;12(5):321-61. [PubMed]
8. Marchesi C. Pharmacological management of panic disorder. Neuropsychiatr Dis Treat. 2008 Feb;4(1):93-106. [PMC free article] [PubMed]
9. Garza-Treviño ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry. 1989 Dec;146(12):1598-601. [PubMed]
10. Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges. Curr Neuropharmacol. 2017;15(5):789-798. [PMC free article] [PubMed]
11. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008 Dec 15;23(16):2267-302. [PubMed]
12. Huynh NT, Rompré PH, Montplaisir JY, Manzini C, Okura K, Lavigne GJ. Comparison of various treatments for sleep bruxism using determinants of number needed to treat and effect size. Int J Prosthodont. 2006 Sep-Oct;19(5):435-41. [PubMed]
13. Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, Karippot A, Ramar K, Kristo DA, Morgenthaler TI., Standards of Practice Committee. American Academy of Sleep Medicine. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010 Feb 15;6(1):85-95. [PMC free article] [PubMed]
14. Tan HL, Smith JG, Hoffmann J, Renton T. A systematic review of treatment for patients with burning mouth syndrome. Cephalalgia. 2022 Feb;42(2):128-161. [PMC free article] [PubMed]
15. Rossella I, Alessandro V, Naman R, Gary K, Hervé SY. Topical clonazepam for burning mouth syndrome: Is it efficacious in patients with anxiety or depression? J Oral Rehabil. 2022 Jan;49(1):54-61. [PubMed]
16. Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. [PMC free article] [PubMed]
17. Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013 Summer;13(2):214-23. [PMC free article] [PubMed]
18. Kacirova I, Grundmann M, Silhan P, Brozmanova H. A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period. Medicine (Baltimore). 2016 Mar;95(9):e2881. [PMC free article] [PubMed]
19. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994 Nov-Dec;8(6):461-75. [PubMed]
20. Payne JL. Psychopharmacology in Pregnancy and Breastfeeding. Psychiatr Clin North Am. 2017 Jun;40(2):217-238. [PubMed]
21. Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996 Jan-Feb;16(1):49-57. [PubMed]
22. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 25, 2017. Clonazepam. [PMC free article] [PubMed]
23. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-694. [PubMed]
24. Stacy M. Sleep disorders in Parkinson's disease: epidemiology and management. Drugs Aging. 2002;19(10):733-9. [PubMed]
25. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. [PubMed]
26. Sorel L, Mechler L, Harmant J. Comparative trial of intravenous lorazepam and clonazepam im status epilepticus. Clin Ther. 1981;4(4):326-36. [PubMed]
27. Lander CM, Donnan GA, Bladin PF, Vajda FJ. Some aspects of the clinical use of clonazepam in refractory epilepsy. Clin Exp Neurol. 1979;16:325-32. [PubMed]
28. Alvarez N, Hartford E, Doubt C. Epileptic seizures induced by clonazepam. Clin Electroencephalogr. 1981 Apr;12(2):57-65. [PubMed]
29. Veall RM, Hogarth HC. Letter: Thrombocytopenia during treatment with clonazepam. Br Med J. 1975 Nov 22;4(5994):462. [PMC free article] [PubMed]
30. Rosenfeld WE, Beniak TE, Lippmann SM, Loewenson RB. Adverse behavioral response to clonazepam as a function of Verbal IQ-Performance IQ discrepancy. Epilepsy Res. 1987 Nov-Dec;1(6):347-56. [PubMed]
31. Dodds TJ. Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature. Prim Care Companion CNS Disord. 2017 Mar 02;19(2) [PubMed]
32. White MC, Silverman JJ, Harbison JW. Psychosis associated with clonazepam therapy for blepharospasm. J Nerv Ment Dis. 1982 Feb;170(2):117-9. [PubMed]
33. Williams A, Gillespie M. Clonazepam-induced incontinence. Ann Neurol. 1979 Jul;6(1):86. [PubMed]
34. Anders RJ, Wang E, Radhakrishnan J, Sharifi R, Lee M. Overflow urinary incontinence due to carbamazepine. J Urol. 1985 Oct;134(4):758-9. [PubMed]
35. Cohen LS, Rosenbaum JF. Clonazepam: new uses and potential problems. J Clin Psychiatry. 1987 Oct;48 Suppl:50-6. [PubMed]
36. Yang HW, Bae JB, Na JI, Kim KW. Clonazepam-induced lichenoid drug eruption: a case report. BMC Psychiatry. 2021 Mar 04;21(1):125. [PMC free article] [PubMed]
37. Ghosh D, Petrecca AM, Khuhro AL. Sleep-Related Eating Disorder (SRED): Paradoxical Effect of Clonazepam. J Clin Sleep Med. 2018 Jul 15;14(7):1261-1263. [PMC free article] [PubMed]
38. Aschenbrenner DS. Stronger Boxed Warning for Benzodiazepines. Am J Nurs. 2021 Mar 01;121(3):22-23. [PubMed]
39. Singh D, Narayanan S, Grundmann O, Boyer EW, Vicknasingam B. The Use of Benzodiazepines among Kratom (*Mitragyna Speciosa* Korth.) Users. J Psychoactive Drugs. 2020 Jan-Mar;52(1):86-92. [PubMed]
40. Montoro J, Bartra J, Sastre J, Dávila I, Ferrer M, Mullol J, del Cuvillo A, Jáuregui I, Valero A. H1 antihistamines and benzodiazepines. Pharmacological interactions and their impact on cerebral function. J Investig Allergol Clin Immunol. 2013;23 Suppl 1:17-26. [PubMed]
41. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006 Mar;61(3):246-55. [PMC free article] [PubMed]
42. Cokley JA, Gidal BE, Keller JA, Vossler DG., Reviewed and approved by the AES Treatments Committee and Council on Clinical Activities. Paxlovid™ Information From FDA and Guidance for AES Members. Epilepsy Curr. 2022 Jun;22(3):201-204. [PMC free article] [PubMed]
43. Razeghinejad MR, Pro MJ, Katz LJ. Non-steroidal drug-induced glaucoma. Eye (Lond). 2011 Aug;25(8):971-80. [PMC free article] [PubMed]
44. Agrawal R, Verma S, Halappanavar M. Measuring the Effectiveness of Benzodiazepine Prescriptions Control in Community Setting Using Prescription Drug Monitoring Program (PDMP). Community Ment Health J. 2021 Jul;57(5):920-925. [PubMed]
45. Karunarathna, I., Gunarathna, I., Dealwis, K., & Abeykoon, M. (February 2024). CLASS III BIOSAFETY COVID ICU: New innovation report. Uva Clinical Lab. Retrieved from https://www.researchgate.net/publication/378403156_Title_CLASS_III_BIOSAFETY_COVID_ICU_New_innovation_report?_sg%5B0%5D=LYHufMg1R3W5b0FrC1sonv9cTQ7nIiQ1wNb2RYKQD11jjzCkduyYZKpCYHfKMamtSa7afTrk2llcr2Bb9GJhindNF5Yudi-4_93O0pYh.tXT_pjGoGZ5BfcePu74-BkNBRjSqOkJjHl7XdACa63eMReNT1VnAmZ-D7mlKDgLDD7i-X8XAFIhRUeOy-snflg&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoicHJvZmlsZSIsInByZXZpb3VzUGFnZSI6InByb2ZpbGUiLCJwb3NpdGlvbiI6InBhZ2VDb250ZW50In19
46. Karunarathna, I., Karunarathna, I., Kusumarathna, K., Jayathilaka, P., & Withanagama, C. J. (May 2024). Comprehensive Review of Metformin: Indications, Contraindications, and Potential Applications. Uva Clinical Lab. Available online: URL
47. Karunarathna, I., Rathnayake, B., Bandara, S., Siriwardana, R., et al. (May 2024). Dexmedetomidine: A Comprehensive Review of Pharmacology, Clinical Applications, and Considerations for Interprofessional Management. Uva Clinical Lab. Available online: Dexmedetomidine: A

Comprehensive Review of Pharmacology, Clinical Applications, and Considerations for Interprofessional Management

48. Withanagama, C., Perera, D., Herath, P. R., Karunarathna, I., et al. (2024, May). Norepinephrine in Hypotension Management: Pharmacokinetics, Strategies, and Collaborative Care. Uva Clinical Lab. Retrieved from Norepinephrine in Hypotension Management: Pharmacokinetics, Strategies, and Collaborative Care.
49. Karunarathna, I., Kusumarathna, K., Jayathilaka, P., Gunarathna, I., et al. (2024, May). Advances in Understanding and Management of Antidiuretic Hormone Disorders: A Comprehensive Review. Uva Clinical Lab. Retrieved from Advances in Understanding and Management of Antidiuretic Hormone Disorders: A Comprehensive Review.
50. Karunarathna, I., Disanayaka, D., & Kurukulasooriya, P. (2024, May). Anaesthetic Challenges and Complications in Thyroidectomy Patients: A Comprehensive Review. Uva Clinical Lab. Retrieved from Anaesthetic Challenges and Complications in Thyroidectomy Patients: A Comprehensive Review.
51. Karunarathna, I. (2024, May). The Impact of Hyperglycemia on Perioperative Outcomes in Patients with Diabetes Mellitus. Uva Clinical Lab. Retrieved from The Impact of Hyperglycemia on Perioperative Outcomes in Patients with Diabetes Mellitus.
52. Karunarathna, I. (2024, May). The Role of Atropine in Modern Medicine: Indications, Administration, and Clinical Outcomes. Uva Clinical Lab. Retrieved from The Role of Atropine in Modern Medicine: Indications, Administration, and Clinical Outcomes.
53. Karunarathna, I., Kusumarathna, K., Jayathilaka, P., & Withanage, C. (2024, May). Comprehensive Management of Hypertension: Strategies, Guidelines, and Emerging Therapies. Uva Clinical Lab. Retrieved from Comprehensive Management of Hypertension: Strategies, Guidelines, and Emerging Therapies.
54. Karunarathna, I. (2024, May). Fentanyl: Clinical Applications and Pharmacological Considerations. Uva Clinical Lab. Retrieved from Fentanyl: Clinical Applications and Pharmacological Considerations.
55. Karunarathna, I. (2024, May). Morphine Sulfate: Clinical Applications and Pharmacological Considerations. Uva Clinical Lab. Retrieved from Morphine Sulfate: Clinical Applications and Pharmacological Considerations.
56. Karunarathna, I. (2024, May). Remifentanil Hydrochloride: A Paradigm Shift in Opioid Analgesia Management. Uva Clinical Lab. Retrieved from Remifentanil Hydrochloride: A Paradigm Shift in Opioid Analgesia Management.
57. Karunarathna, I., Jayathilaka, P. (2024, May). Comprehensive Management of Type 2 Diabetes Mellitus: From Prevention to Novel Therapeutic Approaches. Uva Clinical Lab. Retrieved from Comprehensive Management of Type 2 Diabetes Mellitus: From Prevention to Novel Therapeutic Approaches.
58. Karunarathna, I. (2024, May). Levetiracetam: Mechanism of Action, Pharmacology, and Clinical Applications. Uva Clinical Lab. Retrieved from Levetiracetam: Mechanism of Action, Pharmacology, and Clinical Applications.
59. Karunarathna, I., Withanagama, C., Perera, D., Samarakoon, A. (2024, May). Sugammadex: Revolutionizing Neuromuscular Blockade Reversal in Anesthesia and Critical Care. Uva Clinical Lab. Retrieved from Sugammadex: Revolutionizing Neuromuscular Blockade Reversal in Anesthesia and Critical Care.
60. Karunarathna, I., Tharayil, A. S. (2024, May). Understanding Atracurium: A Guide to Neuromuscular Blockade. Uva Clinical Lab. Retrieved from Understanding Atracurium: A Guide to Neuromuscular Blockade.
61. Karunarathna, I. (2024, May). Ivabradine Therapy in Heart Failure Management: Optimizing Outcomes Through Interprofessional Collaboration. Uva Clinical Lab. Retrieved from Ivabradine Therapy in Heart Failure Management: Optimizing Outcomes Through Interprofessional Collaboration.
62. Karunarathna, I., et al. (2024, May). Desflurane: A Valuable Anaesthetic Agent in Modern Clinical Practice. Uva Clinical Lab. Retrieved from Desflurane: A Valuable Anaesthetic Agent in Modern Clinical Practice.
63. Karunarathna, I., Tharayil, A. S., et al. (2024, May). Unveiling the Potency of Bupivacaine: A Comprehensive Review of Mechanism, Safety, and Clinical Applications. Uva Clinical Lab. Retrieved from Unveiling the Potency of Bupivacaine: A Comprehensive Review of Mechanism, Safety, and Clinical Applications.
64. Karunarathna, I., Kusumarathna, K., Jayathilaka, P., Withanagama, C., et al. (2024, April). Optimizing Fluid Management in Critical Care: Principles and Strategies. Uva Clinical Lab. Retrieved from Optimizing Fluid Management in Critical Care: Principles and Strategies.
65. Karunarathna, I., Kusumarathna, K., Gunarathna, I., Kurukulasooriya, P., et al. (2024, May). Sevoflurane: Pharmacology, Administration, and Safety Considerations in Anesthesia. Uva Clinical Lab. Retrieved from Sevoflurane: Pharmacology, Administration, and Safety Considerations in Anesthesia.
66. Karunarathna, I., Rathnayake, B., Kumari, D., Gunarathna, I., et al. (2024, April). Advancements in the Management of Acute Liver Failure: Pathophysiology, Diagnosis, and Treatment Strategies. Uva Clinical Lab. Retrieved from Advancements in the Management of Acute Liver Failure: Pathophysiology, Diagnosis, and Treatment Strategies.
67. Karunarathna, I., Kusumarathna, K., Jayathilaka, P., Withanagama, C., et al. (2024, April). Optimizing Patient Outcomes through Single-Lung Ventilation in Thoracic Anesthesia: An Integrative Approach. Uva Clinical Lab. Retrieved from Optimizing Patient Outcomes through Single-Lung Ventilation in Thoracic Anesthesia: An Integrative Approach.
68. Karunarathna, Indunil, and K. Kusumarathna. "Optimizing Traumatic Brain Injury Management: A Multidisciplinary Approach and Lessons Learned from a Complex Case." Available from: https://www.researchgate.net/publication/380096567_Optimizing_Traumatic_Brain_Injury_Management_A_Multidisciplinary_Approach_and_Lessons_Learned_from_a_Complex_Case [accessed Apr 25 2024].
69. Karunarathna, Indunil, and K. Kusumarathna. "How to Recognize, Respond to, and Prevent Anaphylaxis: A Comprehensive Guide." Available from: https://www.researchgate.net/publication/380096299_How_to_Recognize_Respond_to_and_Prevent_Anaphylaxis_A_Comprehensive_Guide [accessed Apr 25 2024].
70. Karunarathna, Indunil, K. Kusumarathna, P. Jayathilaka, C. J. Withanagama, and others. "Understanding Evidence Levels in Evidence-Based Medicine: A Guide for Healthcare Professionals." April 2024. Lab: Uva Clinical Lab. Available from: ResearchGate.
71. Karunarathna, Indunil, et al. "Navigating Pediatric Anatomy and Physiology in Anesthesia: Key Considerations for Safe Perioperative Care." Available from: https://www.researchgate.net/publication/380030115_Navigating_Pediatric_Anatomy_and_Physiology_in_Anesthesia_Key_Considerations_for_Safe_Perioperative_Care [accessed Apr 25 2024].
72. Karunarathna, Indunil, et al. "Advancements in Labor Analgesia: Navigating Modern Techniques." Available from: https://www.researchgate.net/publication/380000759_Advancements_in_Labor_Analgesia_Navigating_Modern_Techniques [accessed Apr 25 2024].
73. Karunarathna, Indunil, et al. "Understanding Pain Physiology: Foundations for Effective Chronic Pain Management (Part 2)." Available from: https://www.researchgate.net/publication/379959202_Understanding_Pain_Physiology_Foundations_for_Effective_Chronic_Pain_Management_Part_2 [accessed Apr 25 2024].
74. Karunarathna, Indunil, et al. "Understanding Pain Physiology: Foundations for Effective Chronic Pain Management (Part 1)." Available from: https://www.researchgate.net/publication/379956116_Understanding_Pain_Physiology_Foundations_for_Effective_Chronic_Pain_Management_Part_1 [accessed Apr 25 2024].
75. Karunarathna, Indunil, et al. "Optimizing Perioperative Care for Patients with Chronic Kidney Disease." Available from: https://www.researchgate.net/publication/379907517_Optimizing_Perioperative_Care_for_Patients_with_Chronic_Kidney_Disease [accessed Apr 25 2024].
76. Karunarathna, Indunil, et al. "Intensive Care Management of Tetanus: Current Strategies and Challenges." Available from: https://www.researchgate.net/publication/379892925_Intensive_Care_Management_of_Tetanus_Current_Strategies_and_Challenges [accessed Apr 25 2024].
77. Karunarathna, Indunil, et al. "Anesthesia Considerations for Pregnant Patients: Physiological Changes, Drug Transfer, and Safety Implications." April 2024. Lab: Uva Clinical Lab. Available from: ResearchGate.
78. Karunarathna, Indunil, et al. "Ketamine: Mechanisms, Applications, and Future Directions." Available from: https://www.researchgate.net/publication/379822825_Ketamine_Mechanisms_Applications_and_Future_Directions [accessed Apr 25 2024].
79. Karunarathna, Indunil, et al. "Comprehensive Management of Diabetes Mellitus in the Perioperative Setting: An Anesthesia Perspective." Available from: https://www.researchgate.net/publication/379809223_Comprehensive_Man

agement_of_Diabetes_Mellitus_in_the_Perioperative_Setting_An_Anesthesia_Perspective [accessed Apr 25 2024].
80. Karunarathna, Indunil, et al. "Optimizing Perioperative Fluid Management in Pediatric Patients: Key Considerations and Recommendations." Available from: https://www.researchgate.net/publication/379778668_Optimizing_Perioperative_Fluid_Management_in_Pediatric_Patients_Key_Considerations_and_Recommendations [accessed Apr 25 2024].
81. Karunarathna, Indunil, et al. "Enhancing Perioperative Care: Comprehensive Preoperative Assessment of Functional Capacity." Available from: https://www.researchgate.net/publication/379750071_Enhancing_Perioperative_Care_Comprehensive_Preoperative_Assessment_of_Functional_Capacity [accessed Apr 25 2024].
82. Karunarathna, Indunil, et al. "Anesthetic Management of Valvular Heart Disease in Non-cardiac Surgeries: Insights from Developing Countries." Available from: https://www.researchgate.net/publication/379732046_Anesthetic_Management_of_Valvular_Heart_Disease_in_Non_cardiac_Surgeries_Insights_from_Developing_Countries [accessed Apr 25 2024].
83. Karunarathna, Indunil, et al. "Navigating Pre-eclampsia: Anesthesia and ICU Management Strategies for Maternal and Fetal Well-being." April 2024. Lab: Uva Clinical Lab. Available from: ResearchGate.
84. Karunarathna, Indunil, et al. "Navigating the Asthmatic Airway: Anesthesia Management Strategies and Considerations." Available from: https://www.researchgate.net/publication/379664534_Navigating_the_Asthmatic_Airway_Anesthesia_Management_Strategies_and_Considerations [accessed Apr 25 2024].
85. Karunarathna, Indunil, et al. "Understanding Ventilator-Associated Pneumonia: Causes, Prevention, and Management." Available from: https://www.researchgate.net/publication/379568306_Understanding_Ventilator-Associated_Pneumonia_Causes_Prevention_and_Management [accessed Apr 25 2024].
86. Karunarathna, Indunil, et al. "Advancements in Electroconvulsive Therapy (ECT) and Anesthetic Management: A Comprehensive Review." Available from: https://www.researchgate.net/publication/379374955_Advancements_in_Electroconvulsive_Therapy_ECT_and_Anesthetic_Management_A_Comprehensive_Review [accessed Apr 25 2024].
87. Karunarathna, Indunil, L. De Silva, B. Rathnayake, et al. "ICU Topic: ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) Introduction." March 2024. Conference: Uva Clinical. Lab: Uva Clinical Lab. DOI: 10.13140/RG.2.2.13488.16645. Available from: ResearchGate.
91. Karunarathna, Indunil, et al. "Necrotizing Fasciitis: A Deadly Soft Tissue Infection." Available from: https://www.researchgate.net/publication/379225574_Necrotizing_Fasciitis_A_Deadly_Soft_Tissue_Infection [accessed Apr 25 2024].
92. Karunarathna, Indunil, Konara Kusumarathna, Pradeep Jayathilaka, N. Priyalath, et al. "Mechanical Ventilation." March 2024. Lab: Uva Clinical Lab. Available from: https://www.researchgate.net/publication/378910013_Mechanical_Ventilation
93. Karunarathna, Indunil, Indira Gunarathna, K. Dealwis, and M. Abeykoon. "CLASS III BIOSAFETY COVID ICU: New innovation report." February 2024. Lab: Uva Clinical Lab. DOI: 10.13140/RG.2.2.31505.61285. Available from: ResearchGate.from: https://www.researchgate.net/publication/378403142_CLASS_III_BIOSAFETY_COVID_ICU_New_innovation_report
94. Karunarathna, Indunil, Konara Kusumarathna, and Anura Samarakoon. "Speed of Spinal Anaesthesia Technique for Category-2 Caesarean Section: Clinical Observation-Based Study." February 2024. DOI: 10.13140/RG.2.2.24794.72641. Lab: Uva Clinical Lab. Available from: https://www.researchgate.net/publication/378402970_Speed_of_Spinal_Anaesthesia_Technique_for_Category-2_Caesarean_Section_Clinical_Observation-Based_Study
95. Karunarathna, Indunil, Indira Gunarathna, K. Dealwis, and M. Abeykoon. "CLASS III BIOSAFETY COVID ICU: New innovation report." February 2024. Lab: Uva Clinical Lab. DOI: 10.13140/RG.2.2.31505.61285. Available from: ResearchGate.from: https://www.researchgate.net/publication/378403142_CLASS_III_BIOSAFETY_COVID_ICU_New_innovation_report
96. Karunarathna, Indunil, Konara Kusumarathna, and Anura Samarakoon. "Speed of Spinal Anaesthesia Technique for Category-2 Caesarean Section: Clinical Observation-Based Study." February 2024. DOI: 10.13140/RG.2.2.24794.72641. Lab: Uva Clinical Lab. Available from: https://www.researchgate.net/publication/378402970_Speed_of_Spinal_Anaesthesia_Technique_for_Category-2_Caesarean_Section_Clinical_Observation-Based_Study
97. Karunarathna, I., De Silva, L., Rathnayake, B. (March 2024). "ICU Topic: Acute Respiratory Distress Syndrome (ARDS)." Uva Clinical. DOI: 10.13140/RG.2.2.13488.16645
98. Karunarathna, I., De Silva, L., Rathnayake, B. (March 2024). "ICU Topic: Acute Respiratory Distress Syndrome (ARDS)." Uva Clinical Lab. Retrieved from: https://www.researchgate.net/publication/378709273_ICU_Topic_ACUTE_RESPIRATORY_DISTRESS_SYNDROME_ARDS?_sg%5B0%5D=e0DuHLQU85RjIqCxOsOLm7sdmVokkNYReq7Usfb8htMW-cwi-IDaUFTvngEf2blz-8eGE5zNT2eAKNLFVMP80ujQGYcaSU7R9DHO20bo.eZrvhKqYcaEJuPcxYNN2EpfOV8Y7Pnm7VqFSEFTRagUHtu0VckboG-nFQs-3U1YPSCzXpdl-_3GDSlqOV9zl3A&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoicHJvZmlsZSIsInByZXZpb3VzUGFnZSI6InByb2ZpbGUiLCJwb3NpdGlvbiI6InBhZ2VDb250ZW50In19
99. Karunarathna, I., Gunarathna, I., Dealwis, K., Abeykoon, M. (February 2024). "CLASS III BIOSAFETY COVID ICU: New innovation report." Uva Clinical Lab. Thesis . Retrieved from: https://www.researchgate.net/publication/378403156_Title_CLASS_III_BIOSAFETY_COVID_ICU_New_innovation_report?_sg%5B0%5D=e0DuHLQU85RjIqCxOsOLm7sdmVokkNYReq7Usfb8htMW-cwi-IDaUFTvngEf2blz-8eGE5zNT2eAKNLFVMP80ujQGYcaSU7R9DHO20bo.eZrvhKqYcaEJuPcxYNN2EpfOV8Y7Pnm7VqFSEFTRagUHtu0VckboG-nFQs-3U1YPSCzXpdl-_3GDSlqOV9zl3A&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoicHJvZmlsZSIsInByZXZpb3VzUGFnZSI6InByb2ZpbGUiLCJwb3NpdGlvbiI6InBhZ2VDb250ZW50In19
100. Karunarathna, I., Karunarathna, I., De Silva, L., Rathnayake, B. (March 2024). "ICU Topic: Acute Respiratory Distress Syndrome (ARDS) Introduction." Conference: Uva Clinical. Lab: Uva Clinical Lab. Available from: [https://www.researchgate.net/publication/379332417_ICU_Topic_ACUTE_RESPIRATORY_DISTRESS_SYNDROME_ARDS_Introduction?_sg%5B0%5D=QAxTpc1nbRhf8EyDskXaY5UoCHGuQUWj7XTg5h_S-KHZHE8linyM-AaPXSspcUUXpLaCGYEeSVCHRGf2mfDEpXPMW9ITVXEZpF1j06M2.iDpFx41wFcZ8Oi_XrotG6cEiJUPN2JXt6o684ZOj-p0vwOS1Msl26iM0hm-63-oYJIWB6LSDXHkCL9Z9MnqT1w&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoicHJvZmlsZSIsInByZXZpb3VzUGFnZSI6InByb2ZpbGUiLCJwb3NpdGlvbiI6InBhZ2VDb250ZW50In19
102. Karunarathna, I., Gunarathna, I., Dealwis, K., & Abeykoon, M. (February 2024). CLASS III BIOSAFETY COVID ICU: New innovation report. Uva Clinical Lab. Retrieved from https://www.researchgate.net/publication/378403156_Title_CLASS_III_BIOSAFETY_COVID_ICU_New_innovation_report

103. Greenblatt DJ, Allen MD, Noel BJ, Shader RI. Acute overdosage with benzodiazepine derivatives. Clin Pharmacol Ther. 1977 Apr;21(4):497-514. [PubMed]
104. Thomson JS, Donald C, Lewin K. Use of Flumazenil in benzodiazepine overdose. Emerg Med J. 2006 Feb;23(2):162. [PMC free article] [PubMed]
105. Sarangi A, McMahon T, Gude J. Benzodiazepine Misuse: An Epidemic Within a Pandemic. Cureus. 2021 Jun;13(6):e15816. [PMC free article] [PubMed]
106. Aldy K, Mustaquim D, Campleman S, Meyn A, Abston S, Krotulski A, Logan B, Gladden MR, Hughes A, Amaducci A, Shulman J, Schwarz E, Wax P, Brent J, Manini A., Toxicology Investigators Consortium Fentalog Study Group. Notes from the Field: Illicit Benzodiazepines Detected in Patients Evaluated in Emergency Departments for Suspected Opioid Overdose - Four States, October 6, 2020-March 9, 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1177-1179. [PMC free article] [PubMed]
107. Furbish SML, Kroehl ME, Loeb DF, Lam HM, Lewis CL, Nelson J, Chow Z, Trinkley KE. A Pharmacist-Physician Collaboration to Optimize Benzodiazepine Use for Anxiety and Sleep Symptom Control in Primary Care. J Pharm Pract. 2017 Aug;30(4):425-433. [PMC free article] [PubMed]